BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology. 2003;125:32-39. [PMID: 12851868 DOI: 10.1016/s0016-5085(03)00701-7] [Cited by in Crossref: 238] [Cited by in F6Publishing: 63] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73. [PMID: 25609972 DOI: 10.2147/TCRM.S55506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
2 Naseer M, Kulairi Z, Kam M. Cardiac Tamponade as a Presenting Manifestation of Infliximab-Induced Lupus in Patient Treated for Crohn's Disease.ACG Case Rep J. 2017;4:e1. [PMID: 28138445 DOI: 10.14309/crj.2017.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
3 De Bandt M. Anti-TNF-alpha-induced lupus. Arthritis Res Ther 2019;21:235. [PMID: 31718696 DOI: 10.1186/s13075-019-2028-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
4 Travassos WJ, Cheifetz AS. Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005;8:187-196. [PMID: 15913508 DOI: 10.1007/s11938-005-0011-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
5 Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008;10:202. [PMID: 18226185 DOI: 10.1186/ar2341] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 7.5] [Reference Citation Analysis]
6 O'Toole A, Lucci M, Korzenik J. Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA. Dig Dis Sci. 2016;61:1772-1774. [PMID: 26728477 DOI: 10.1007/s10620-015-4007-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
7 Salvi M, Macaluso L, Luci C, Mattozzi C, Paolino G, Aprea Y, Calvieri S, Richetta AG. Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C. World J Clin Cases 2016; 4(2): 49-55 [PMID: 26881191 DOI: 10.12998/wjcc.v4.i2.49] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
8 Selvam S, Thomas PB, Hamm-Alvarez SF, Schechter JE, Stevenson D, Mircheff AK, Trousdale MD. Current status of gene delivery and gene therapy in lacrimal gland using viral vectors. Adv Drug Deliv Rev 2006;58:1243-57. [PMID: 17056149 DOI: 10.1016/j.addr.2006.07.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
9 Seow CH, de Silva S, Kaplan GG, Devlin SM, Ghosh S, Panaccione R. Managing the risks of IBD therapy. Curr Gastroenterol Rep 2009;11:509-17. [PMID: 19903428 DOI: 10.1007/s11894-009-0077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 Domènech E, Garcia-Planella E, Olazábal A, Sánchez-Delgado J, Zabana Y, Bernal I, Mañosa M, Olivé A, Gassull MA. Abdominal aortitis associated with Crohn's disease. Dig Dis Sci 2005;50:1122-3. [PMID: 15986866 DOI: 10.1007/s10620-005-2716-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
11 Poggioli G, Laureti S, Campieri M, Pierangeli F, Gionchetti P, Ugolini F, Gentilini L, Bazzi P, Rizzello F, Coscia M. Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag 2007;3:301-8. [PMID: 18360638 DOI: 10.2147/tcrm.2007.3.2.301] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
12 Fonseca A, Sunny J, Felipez LM. Antitumor Necrosis Factor-Alpha (TNF-α) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease. Case Rep Pediatr 2021;2021:9989729. [PMID: 34336341 DOI: 10.1155/2021/9989729] [Reference Citation Analysis]
13 Richez C, Schaeverbeke T, Dumoulin C, Dehais J, Moreau JF, Blanco P. Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab. Arthritis Res Ther 2009;11:R100. [PMID: 19563672 DOI: 10.1186/ar2746] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
14 Mendonça JA, Marques-Neto JF, Samara AM, Appenzeller S. Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis. Rheumatol Int 2012;32:815-8. [PMID: 21327431 DOI: 10.1007/s00296-011-1812-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
15 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
16 Aybay C, Ozel S, Aybay C. Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis. Rheumatol Int 2006;26:473-80. [PMID: 16341700 DOI: 10.1007/s00296-005-0085-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
17 Kocsis D, Tóth Z, Csontos ÁA, Miheller P, Pák P, Herszényi L, Tóth M, Tulassay Z, Juhász M. Prevalence of inflammatory bowel disease among coeliac disease patients in a Hungarian coeliac centre. BMC Gastroenterol 2015;15:141. [PMID: 26481725 DOI: 10.1186/s12876-015-0370-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
18 Choi SJ, Ahn SM, Oh JS, Hong S, Lee CK, Yoo B, Ye BD, Yang SK, Park SH, Kim YG. Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea. Therap Adv Gastroenterol 2021;14:1756284821997794. [PMID: 33747126 DOI: 10.1177/1756284821997794] [Reference Citation Analysis]
19 Veisman I, Barzilay O, Bruckmayer L, Haj-Natour O, Kopylov U, Eliakim R, Ben-Horin S, Ungar B. Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study. J Clin Med 2021;10:4265. [PMID: 34575376 DOI: 10.3390/jcm10184265] [Reference Citation Analysis]
20 Rott S, Mrowietz U. Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ 2005;330:716-20. [PMID: 15790644 DOI: 10.1136/bmj.330.7493.716] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
21 Mukhtyar C, Luqmani R. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann Rheum Dis 2005;64 Suppl 4:iv31-6. [PMID: 16239383 DOI: 10.1136/ard.2005.042416] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
22 Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017; 9(13): 613-626 [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
23 Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Andreou NP, Gazouli M, Koutroubakis IE. Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease. Int J Colorectal Dis 2022. [PMID: 35013823 DOI: 10.1007/s00384-021-04091-6] [Reference Citation Analysis]
24 Pereira Vaz JL, Ferreira Andrade CA, Cardoso Pereira A, Martins MDFM, Abramino Levy R. Revisão sistemática da indução de autoanticorpos e lúpus eritematoso pelo infliximabe. Revista Brasileira de Reumatologia 2013;53:358-64. [DOI: 10.1590/s0482-50042013000400008] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
25 Bender NK, Heilig CE, Dröll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007;27:269-274. [PMID: 17006705 DOI: 10.1007/s00296-006-0183-7] [Cited by in Crossref: 106] [Cited by in F6Publishing: 102] [Article Influence: 6.6] [Reference Citation Analysis]
26 Al-Ansari RY, Khuraim AA, Abdalla L, Hamid H, Zakary NY. Remsima (a Tumor Necrosis Factor (TNF) -α Inhibitor) induced hemolysis in a patient with Crohn's disease - Case report. Ann Med Surg (Lond) 2021;69:102768. [PMID: 34484733 DOI: 10.1016/j.amsu.2021.102768] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Huang BC, Lu YC, Liao JM, Liu HJ, Hong ST, Hsieh YC, Chuang CH, Chen HJ, Liao TY, Ho KW, Wang YT, Cheng TL. Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies. Chem Sci 2021;12:9759-69. [PMID: 34349949 DOI: 10.1039/d1sc01748a] [Reference Citation Analysis]
28 Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ, Rioux JD. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008;4:e1000024. [PMID: 18437207 DOI: 10.1371/journal.pgen.1000024] [Cited by in Crossref: 374] [Cited by in F6Publishing: 333] [Article Influence: 26.7] [Reference Citation Analysis]
29 Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review. World J Gastroenterol 2013; 19(44): 7867-7873 [PMID: 24307780 DOI: 10.3748/wjg.v19.i44.7867] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
30 Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2015;3:103-9. [PMID: 25344680 DOI: 10.1093/gastro/gou070] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
31 Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496-503. [PMID: 22751454 DOI: 10.1038/nrgastro.2012.125] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 11.6] [Reference Citation Analysis]
32 Cockx M, Van Hoovels L, De Langhe E, Lenaerts J, Thevissen K, Persy B, Bonroy C, Vercammen M, Bossuyt X. Laboratory evaluation of anti-dsDNA antibodies. Clin Chim Acta 2022:S0009-8981(21)00458-7. [PMID: 35016875 DOI: 10.1016/j.cca.2021.12.029] [Reference Citation Analysis]
33 Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067-2073 [PMID: 19418577 DOI: 10.3748/wjg.15.2067] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
34 Fernando MM, Stevens CR, Sabeti PC, Walsh EC, McWhinnie AJ, Shah A, Green T, Rioux JD, Vyse TJ. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet 2007;3:e192. [PMID: 17997607 DOI: 10.1371/journal.pgen.0030192] [Cited by in Crossref: 116] [Cited by in F6Publishing: 105] [Article Influence: 8.3] [Reference Citation Analysis]
35 de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101. [PMID: 20134491 DOI: 10.1038/nrgastro.2009.221] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
36 Kyriakos N, Papaefthymiou A, Giakoumis M, Iatropoulos G, Mantzaris G, Liatsos C. Informed consent in inflammatory bowel disease: a necessity in real-world clinical practice. Ann Gastroenterol 2021;34:466-75. [PMID: 34276184 DOI: 10.20524/aog.2021.0635] [Reference Citation Analysis]
37 Steeland S, Puimège L, Vandenbroucke RE, Van Hauwermeiren F, Haustraete J, Devoogdt N, Hulpiau P, Leroux-Roels G, Laukens D, Meuleman P, De Vos M, Libert C. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J Biol Chem 2015;290:4022-37. [PMID: 25538244 DOI: 10.1074/jbc.M114.617787] [Cited by in Crossref: 49] [Cited by in F6Publishing: 27] [Article Influence: 6.1] [Reference Citation Analysis]
38 Alivernini S, Pugliese D, Tolusso B, Bui L, Petricca L, Guidi L, Mirone L, Rapaccini GL, Federico F, Ferraccioli G, Armuzzi A, Gremese E. Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. RMD Open 2018;4:e000667. [PMID: 29657833 DOI: 10.1136/rmdopen-2018-000667] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
39 Mir FA, Juboori AA, Bragg JD, Tahan V. Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis. North Clin Istanb 2018;5:64-6. [PMID: 29607436 DOI: 10.14744/nci.2017.77045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Qiu Y, Mao R, Chen MH. A De Novo Arisen Case of Primary Adrenal Insufficiency in an Adolescent Patient With Crohn Disease: A Case report. Medicine (Baltimore). 2015;94:e818. [PMID: 26061303 DOI: 10.1097/md.0000000000000818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Click B, Regueiro M. A Practical Guide to the Safety and Monitoring of New IBD Therapies. Inflamm Bowel Dis. 2019;25:831-842. [PMID: 30312391 DOI: 10.1093/ibd/izy313] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
42 Caprioli F, Caruso R, Sarra M, Pallone F, Monteleone G. Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases. Br J Pharmacol 2012;165:820-8. [PMID: 21806600 DOI: 10.1111/j.1476-5381.2011.01614.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
43 Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004;6:R264-72. [PMID: 15142273 DOI: 10.1186/ar1173] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 5.7] [Reference Citation Analysis]
44 Strik AS, D'Haens GR, Löwenberg M. Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report. Clin Case Rep 2019;7:2049-53. [PMID: 31788249 DOI: 10.1002/ccr3.2394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Dinesen L, Travis S. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). Int J Nanomedicine 2007;2:39-47. [PMID: 17722511 DOI: 10.2147/nano.2007.2.1.39] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
46 Virupannavar S, Brandau A, Guggenheim C, Laird-Fick H. Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome. Case Rep Rheumatol. 2014;2014:801072. [PMID: 24949211 DOI: 10.1155/2014/801072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
47 Nagasu A, Mukai T, Iseki M, Kawahara K, Tsuji S, Nagasu H, Ueki Y, Ishihara K, Kashihara N, Morita Y. Sh3bp2 Gain-Of-Function Mutation Ameliorates Lupus Phenotypes in B6.MRL-Faslpr Mice. Cells 2019;8:E402. [PMID: 31052273 DOI: 10.3390/cells8050402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
48 Papamichael K, Cheifetz AS. Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. Expert Opinion on Drug Metabolism & Toxicology. [DOI: 10.1080/17425255.2021.2027367] [Reference Citation Analysis]
49 Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777. [PMID: 15301561 DOI: 10.2165/00003495-200464160-00004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
50 Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016;9:513-26. [PMID: 27366220 DOI: 10.1177/1756283X16638833] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
51 Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004;6:R535-43. [PMID: 15535831 DOI: 10.1186/ar1440] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 4.8] [Reference Citation Analysis]
52 López P, Gutiérrez C, Suárez A. IL-10 and TNFalpha genotypes in SLE. J Biomed Biotechnol 2010;2010:838390. [PMID: 20625422 DOI: 10.1155/2010/838390] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
53 Thurlapati A, Gandu SSK, Kulkarni S. Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn's Disease. Cureus 2021;13:e15835. [PMID: 34327073 DOI: 10.7759/cureus.15835] [Reference Citation Analysis]
54 Siegel CA. Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis 2010;16:2168-72. [PMID: 20848508 DOI: 10.1002/ibd.21305] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
55 Verma M, Hontecillas R, Abedi V, Leber A, Tubau-Juni N, Philipson C, Carbo A, Bassaganya-Riera J. Modeling-Enabled Systems Nutritional Immunology. Front Nutr 2016;3:5. [PMID: 26909350 DOI: 10.3389/fnut.2016.00005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
56 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
57 Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-73. [PMID: 15306602 DOI: 10.1136/gut.2003.025452] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
58 Kuhbacher T, Fölsch U. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol 2007; 13(8): 1149-1155 [PMID: 17451192 DOI: 10.3748/wjg.v13.i8.1149] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
59 Bengi G, Cıvak M, Akarsu M, Soytürk M, Ellidokuz E, Topalak Ö, Akpınar H. Prevalance of Celiac Disease in Patients with Inflammatory Bowel Disease in Turkish Population. Gastroenterol Res Pract 2019;2019:6272098. [PMID: 31885543 DOI: 10.1155/2019/6272098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Click B, Regueiro M. Managing Risks with Biologics. Curr Gastroenterol Rep 2019;21:1. [PMID: 30635807 DOI: 10.1007/s11894-019-0669-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
61 Puertas-Abreu E, Polanco ER, Azocar M, Mundarain LA, Nuñez-Sotelo CM, Montaño R, Vivas FH, Noguera ZT, Marín F, Bellorin O, Rivas JG, Toro E, Benzaquen E, Rauseo M, Gutiérrez González LA; GRUPO GRUVES: grupo Venezolano para el Estudio de las Espondiloartritis. Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α. Int Arch Med 2012;5:7. [PMID: 22336076 DOI: 10.1186/1755-7682-5-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
62 D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56:725-32. [PMID: 17440187 DOI: 10.1136/gut.2006.103564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
63 Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, Gjertson D, Braun J, Reed E, Singh RR. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126:121-136. [PMID: 17916444 DOI: 10.1016/j.clim.2007.08.013] [Cited by in Crossref: 182] [Cited by in F6Publishing: 182] [Article Influence: 12.1] [Reference Citation Analysis]
64 Reimold AM. The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol 2012;4:33-47. [PMID: 27790010 DOI: 10.2147/OARRR.S14569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
65 Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011;34:357-74. [PMID: 21513360 DOI: 10.2165/11588500-000000000-00000] [Cited by in Crossref: 65] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
66 Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 2010;9:482-93. [PMID: 20489699 DOI: 10.1038/nrd3030] [Cited by in F6Publishing: 256] [Reference Citation Analysis]
67 Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005;64:403-7. [PMID: 15297281 DOI: 10.1136/ard.2004.024182] [Cited by in Crossref: 142] [Cited by in F6Publishing: 123] [Article Influence: 7.9] [Reference Citation Analysis]
68 Bianco C, Coluccio E, Prati D, Valenti L. Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. J Clin Med 2021;10:423. [PMID: 33499290 DOI: 10.3390/jcm10030423] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci 2006;21:946-9. [PMID: 17043436 DOI: 10.3346/jkms.2006.21.5.946] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]